2024 ICD-10-CM Diagnosis Code T38.811D

Poisoning by anterior pituitary [adenohypophyseal] hormones, accidental (unintentional), subsequent encounter

ICD-10-CM Code:
T38.811D
ICD-10 Code for:
Poisoning by anterior pituitary hormones, accidental, subs
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Not chronic
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      (T36-T50)
      • Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified
        (T38)

T38.811D is a billable diagnosis code used to specify a medical diagnosis of poisoning by anterior pituitary [adenohypophyseal] hormones, accidental (unintentional), subsequent encounter. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.

T38.811D is a subsequent encounter code, includes a 7th character and should be used after the patient has completed active treatment for a condition like poisoning by anterior pituitary [adenohypophyseal] hormones accidental (unintentional). According to ICD-10-CM Guidelines a "subsequent encounter" occurs when the patient is receiving routine care for the condition during the healing or recovery phase of treatment. Subsequent diagnosis codes are appropriate during the recovery phase, no matter how many times the patient has seen the provider for this condition. If the provider needs to adjust the patient's care plan due to a setback or other complication, the encounter becomes active again.

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Accidental corticotropin poisoning
  • Accidental somatropin poisoning
  • Accidental thyrotrophic hormone poisoning
  • Corticotrophic hormone overdose
  • Poisoning by anterior pituitary hormone
  • Poisoning by corticotropin
  • Poisoning caused by somatropin
  • Thyrotrophic hormone poisoning

Clinical Classification

Clinical Information

  • Cosyntropin

    a synthetic peptide that is identical to the 24-amino acid segment at the n-terminal of adrenocorticotropic hormone. acth (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex.
  • Dwarfism, Pituitary

    a form of dwarfism caused by complete or partial growth hormone deficiency, resulting from either the lack of growth hormone-releasing factor from the hypothalamus or from the mutations in the growth hormone gene (gh1) in the pituitary gland. it is also known as type i pituitary dwarfism. human hypophysial dwarf is caused by a deficiency of human growth hormone during development.
  • Growth Hormone

    a polypeptide that is secreted by the adenohypophysis (pituitary gland, anterior). growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. species-specific growth hormones have been synthesized.
  • Growth Hormone-Releasing Hormone

    a peptide of 44 amino acids in most species that stimulates the release and synthesis of growth hormone. ghrf (or grf) is synthesized by neurons in the arcuate nucleus of the hypothalamus. after being released into the pituitary portal circulation, ghrf stimulates gh release by the somatotrophs in the pituitary gland.
  • Growth Hormone-Secreting Pituitary Adenoma

    a pituitary tumor that secretes growth hormone. in humans, excess human growth hormone leads to acromegaly.
  • Human Growth Hormone

    a 191-amino acid polypeptide hormone secreted by the human adenohypophysis (pituitary gland, anterior), also known as gh or somatotropin. synthetic growth hormone, termed somatropin, has replaced the natural form in therapeutic usage such as treatment of dwarfism in children with growth hormone deficiency.
  • Laron Syndrome

    an autosomal recessive disorder characterized by short stature, defective growth hormone receptor, and failure to generate insulin-like growth factor i by growth hormone. laron syndrome is not a form of primary pituitary dwarfism (growth hormone deficiency dwarfism) but the result of mutation of the human ghr gene on chromosome 5.
  • Receptors, Ghrelin

    transmembrane proteins that recognize and bind ghrelin, a potent stimulator of growth hormone secretion and food intake in mammals. ghrelin receptors are found in the pituitary and hypothalamus. they belong to the family of g-protein-coupled receptors.
  • Receptors, Somatotropin

    cell surface proteins that bind growth hormone with high affinity and trigger intracellular changes influencing the behavior of cells. activation of growth hormone receptors regulates amino acid transport through cell membranes, rna translation to protein, dna transcription, and protein and amino acid catabolism in many cell types. many of these effects are mediated indirectly through stimulation of the release of somatomedins.
  • Sermorelin

    the biologically active fragment of human growth hormone-releasing factor, consisting of ghrh(1-29)-amide. this n-terminal sequence is identical in several mammalian species, such as human, pig, and cattle. it is used to diagnose or treat patients with growth hormone deficiency.
  • Glycoprotein Hormones, alpha Subunit

    the alpha chain of pituitary glycoprotein hormones (thyrotropin; follicle stimulating hormone; luteinizing hormone) and the placental chorionic gonadotropin. within a species, the alpha subunits of these four hormones are identical; the distinct functional characteristics of these glycoprotein hormones are determined by the unique beta subunits. both subunits, the non-covalently bound heterodimers, are required for full biologic activity.
  • Gonadotropin-Releasing Hormone

    a decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, luteinizing hormone and follicle stimulating hormone. gnrh is produced by neurons in the septum preoptic area of the hypothalamus and released into the pituitary portal blood, leading to stimulation of gonadotrophs in the anterior pituitary gland.
  • Hyperpituitarism

    disease of the glandular, anterior portion of the pituitary (pituitary gland, anterior) resulting in hypersecretion of adenohypophyseal hormones such as growth hormone; prolactin; thyrotropin; luteinizing hormone; follicle stimulating hormone ; and adrenocorticotropic hormone. hyperpituitarism usually is caused by a functional adenoma.
  • Luteinizing Hormone

    a major gonadotropin secreted by the adenohypophysis (pituitary gland, anterior). luteinizing hormone regulates steroid production by the interstitial cells of the testis and the ovary. the preovulatory luteinizing hormone surge in females induces ovulation, and subsequent luteinization of the follicle. luteinizing hormone consists of two noncovalently linked subunits, alpha and beta. within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (tsh, lh and fsh), but the beta subunit is unique and confers its biological specificity.
  • Luteinizing Hormone, beta Subunit

    the beta subunit of luteinizing hormone. it is a 15-kda glycopolypeptide with structure similar to the beta subunit of the placental chorionic gonadatropin (chorionic gonadotropin, beta subunit, human) except for the additional 31 amino acids at the c-terminal of cg-beta. full biological activity of lh requires the non-covalently bound heterodimers of an alpha and a beta subunit. mutation of the lhb gene causes hypogonadism and infertility.
  • Receptors, LH

    those protein complexes or molecular sites on the surfaces and cytoplasm of gonadal cells that bind luteinizing or chorionic gonadotropic hormones and thereby cause the gonadal cells to synthesize and secrete sex steroids. the hormone-receptor complex is internalized from the plasma membrane and initiates steroid synthesis.
  • Receptors, LHRH

    receptors with a 6-kda protein on the surfaces of cells that secrete luteinizing hormone or follicle stimulating hormone, usually in the adenohypophysis. luteinizing hormone-releasing hormone binds to these receptors, is endocytosed with the receptor and, in the cell, triggers the release of luteinizing hormone or follicle stimulating hormone by the cell. these receptors are also found in rat gonads. inhibins prevent the binding of gnrh to its receptors.
  • Menotropins

    extracts of urine from menopausal women that contain high concentrations of pituitary gonadotropins, follicle stimulating hormone and luteinizing hormone. menotropins are used to treat infertility. the fsh:lh ratio and degree of purity vary in different preparations.
  • Hyperprolactinemia

    increased levels of prolactin in the blood, which may be associated with amenorrhea and galactorrhea. relatively common etiologies include prolactinoma, medication effect, kidney failure, granulomatous diseases of the pituitary gland, and disorders which interfere with the hypothalamic inhibition of prolactin release. ectopic (non-pituitary) production of prolactin may also occur. (from joynt, clinical neurology, 1992, ch36, pp77-8)
  • Lactotrophs

    anterior pituitary cells that produce prolactin.
  • Prolactin

    a lactogenic hormone secreted by the adenohypophysis (pituitary gland, anterior). it is a polypeptide of approximately 23 kd. besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate.
  • Prolactin Release-Inhibiting Factors

    a number of peptides with inhibitory activities on prolactin release have been isolated from the hypothalamus, the peripheral nervous system, and the gut. these include somatostatin, and peptides derived from pomc and precursor for vasopressin-associated neurophysin. biogenic amine dopamine is also a potent pif.
  • Prolactinoma

    a pituitary adenoma which secretes prolactin, leading to hyperprolactinemia. clinical manifestations include amenorrhea; galactorrhea; impotence; headache; visual disturbances; and cerebrospinal fluid rhinorrhea.
  • Prolactin-Releasing Hormone

    a hypothalamic hormone that is synthesized as a precursor protein which is cleaved into two peptides. in addition to stimulating prolactin release the peptides bind to specific g-protein-coupled receptors found at locations within the brain.
  • Receptors, Prolactin

    labile proteins on or in prolactin-sensitive cells that bind prolactin initiating the cells' physiological response to that hormone. mammary casein synthesis is one of the responses. the receptors are also found in placenta, liver, testes, kidneys, ovaries, and other organs and bind and respond to certain other hormones and their analogs and antagonists. this receptor is related to the growth hormone receptor.
  • Urofollitropin

    a protein extract of human menopausal urine in which luteinizing hormone has been partially or completely removed. urofollitropin represents follicle stimulating hormone from the urine.

Coding Guidelines

When coding a poisoning or reaction to the improper use of a medication (e.g., overdose, wrong substance given or taken in error, wrong route of administration), first assign the appropriate code from categories T36-T50. The poisoning codes have an associated intent as their 5th or 6th character (accidental, intentional self-harm, assault and undetermined. If the intent of the poisoning is unknown or unspecified, code the intent as accidental intent. The undetermined intent is only for use if the documentation in the record specifies that the intent cannot be determined. Use additional code(s) for all manifestations of poisonings.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified (T38). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Present on Admission (POA)

T38.811D is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.

CMS POA Indicator Options and Definitions

POA IndicatorReason for CodeCMS will pay the CC/MCC DRG?
YDiagnosis was present at time of inpatient admission.YES
NDiagnosis was not present at time of inpatient admission.NO
UDocumentation insufficient to determine if the condition was present at the time of inpatient admission.NO
WClinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission.YES
1Unreported/Not used - Exempt from POA reporting. NO

Convert T38.811D to ICD-9-CM

  • ICD-9-CM Code: V58.89 - Other specfied aftercare
    Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Table of Drugs and Chemicals

The parent code T38.811 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
ACTHT38.811T38.812T38.813T38.814T38.815T38.816
Adrenocorticotrophic hormoneT38.811T38.812T38.813T38.814T38.815T38.816
AdrenocorticotrophinT38.811T38.812T38.813T38.814T38.815T38.816
AlsactideT38.811T38.812T38.813T38.814T38.815T38.816
Anterior pituitary hormone NECT38.811T38.812T38.813T38.814T38.815T38.816
CorticotropinT38.811T38.812T38.813T38.814T38.815T38.816
CosyntropinT38.811T38.812T38.813T38.814T38.815T38.816
Follicle-stimulating hormone, humanT38.811T38.812T38.813T38.814T38.815T38.816
FSHT38.811T38.812T38.813T38.814T38.815T38.816
Growth hormoneT38.811T38.812T38.813T38.814T38.815T38.816
HGH (human growth hormone)T38.811T38.812T38.813T38.814T38.815T38.816
Luteinizing hormoneT38.811T38.812T38.813T38.814T38.815T38.816
MenotropinsT38.811T38.812T38.813T38.814T38.815T38.816
PergonalT38.811T38.812T38.813T38.814T38.815T38.816
ProlactinT38.811T38.812T38.813T38.814T38.815T38.816
SeractideT38.811T38.812T38.813T38.814T38.815T38.816
SomatotropinT38.811T38.812T38.813T38.814T38.815T38.816
SomatremT38.811T38.812T38.813T38.814T38.815T38.816
SomatropinT38.811T38.812T38.813T38.814T38.815T38.816
TetracosactideT38.811T38.812T38.813T38.814T38.815T38.816
TetracosactrinT38.811T38.812T38.813T38.814T38.815T38.816
Thyreotrophic hormoneT38.811T38.812T38.813T38.814T38.815T38.816
ThyrotrophinT38.811T38.812T38.813T38.814T38.815T38.816
Thyrotropic hormoneT38.811T38.812T38.813T38.814T38.815T38.816
TSHT38.811T38.812T38.813T38.814T38.815T38.816
UrofollitropinT38.811T38.812T38.813T38.814T38.815T38.816

Patient Education


Hormones

Hormones are your body's chemical messengers. They travel in your bloodstream to tissues or organs. They work slowly, over time, and affect many different processes, including:

  • Growth and development
  • Metabolism - how your body gets energy from the foods you eat
  • Sexual function
  • Reproduction
  • Mood

Endocrine glands, which are special groups of cells, make hormones. The major endocrine glands are the pituitary, pineal, thymus, thyroid, adrenal glands, and pancreas. In addition, men produce hormones in their testes and women produce them in their ovaries.

Hormones are powerful. It takes only a tiny amount to cause big changes in cells or even your whole body. That is why too much or too little of a certain hormone can be serious. Laboratory tests can measure the hormone levels in your blood, urine, or saliva. Your health care provider may perform these tests if you have symptoms of a hormone disorder. Home pregnancy tests are similar - they test for pregnancy hormones in your urine.


[Learn More in MedlinePlus]

Medication Errors

Medicines treat infectious diseases, prevent problems from chronic diseases, and ease pain. But medicines can also cause harmful reactions if not used correctly. Errors can happen in the hospital, at the health care provider's office, at the pharmacy, or at home. You can help prevent errors by:

  • Knowing your medicines. When you get a prescription, ask the name of the medicine and check to make sure that the pharmacy gave you the right medicine. Make sure that you understand how often you should take the medicine and how long you should take it.
  • Keeping a list of medicines.
    • Write down all of the medicines that you are taking, including the names of your medicines, how much you take, and when you take them. Make sure to include any over-the-counter medicines, vitamins, supplements, and herbs that you take.
    • List the medicines that you are allergic to or that have caused you problems in the past.
    • Take this list with you every time you see a health care provider.
  • Reading medicine labels and following the directions. Don't just rely on your memory - read the medication label every time. Be especially careful when giving medicines to children.
  • Asking questions. If you don't know the answers to these questions, ask your health care provider or pharmacist:
    • Why am I taking this medicine?
    • What are the common side effects?
    • What should I do if I have side effects?
    • When should I stop this medicine?
    • Can I take this medicine with the other medicines and supplements on my list?
    • Do I need to avoid certain foods or alcohol while taking this medicine?

Food and Drug Administration


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.